Compare Recursion Pharmaceuticals Inc (RXRX) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ProShares UltraPro QQQ ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while ProShares UltraPro QQQ ETF trades at $74.44. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | TQQQ | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $6.79 | $87.22 |
52-Week Low | $2.84 | $37.89 |
Enterprise Value | $1.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
TQQQ trades at $75.13, up 1.82% with a bullish technical signal supported by moving averages. The ETF leverages Nasdaq-100 exposure, amplified by 3x daily returns. Recent institutional buying includes Bay Colony Advisory's 7,786 share acquisition. Technical indicators show RSI at 74.38 suggesting overbought conditions, while ADX indicates strong trend momentum. Support levels begin at $72 with resistance at $74-$76.
Outlook remains positive given AI-driven tech momentum, but leverage amplifies volatility risks. The ETF's structural costs compound daily, potentially eroding long-term returns despite short-term gains. Investors face significant downside risk during market corrections, as evidenced by recent 14% single-day declines. Current levels warrant caution despite bullish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
